Substratum of Proof LGBTQs Are Mentally Ill: HIV Prevention Trials Network (HPTN) announces initiation of HPTN 084

(FHI360) The HIV Prevention Trials Network (HPTN) today announced the initiation of HPTN 084, a Phase 3 double-blind safety and efficacy study of long-acting injectable cabotegravir (CAB) compared to a combination of daily oral tenofovir disoproxil fumarate 300 mg plus emtricitabine 200 mg (TDF/FTC).